Recruiting
PHASE2
INTERVENTIONAL
NCT06584006
Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
To evaluate the efficacy and safety of Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections in the treatment of lymphocytopenia in patients with malignant hematological tumors
Detailed Description
A prospective, randomized controlled study is proposed to evaluate the efficacy and safety of Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections, Recombinant Human Interleukin-2 Injections as a monotherapy, and a non-intervention group. Follow-up observations will also be conducted.
Interventions
Name:
Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections
Type:
DRUG
Description:
Thymalfasin for injection 1.6mg subcutaneous injection once daily (qd) for 7 days, and Recombinant Human Interleukin-2 Injections 1 million units subcutaneous injection qd for 7 days.
Name:
Recombinant Human Interleukin-2 Injections
Type:
DRUG
Description:
Recombinant Human Interleukin-2 Injections 1 million units subcutaneous injection qd for 7 days.
Primary Outcomes
Measure:
Lymphocyte count and its subgroup count
TimeFrame:
Up to 36 months
Description:
Dynamic changes in lymphocyte count and its subgroup count
Trial Information
NCT ID
NCT06584006
Status
Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
The First Affiliated Hospital of Xiamen University
Last Updated
December 15, 2025